| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Cucurbitacin E, a naturally occurring triterpene analog isolated from the climbing stem of Cucumic melo L with a potential therapeutic agent for metabolic diseases, significantly suppresses the activity of the cyclin B1/CDC2 complex. Cucurbitacin E (CuE) was found to reduce adipogenesis in murine adipocytes. CuE treatment diminished hypertrophy of adipocytes, visceral obesity and lipogenesis gene expression in diet induced mice model of metabolic syndrome (MetS). CuE also ameliorated adipose tissue dysfunction by reducing hyperleptinemia and TNF-alpha levels and enhancing hypoadiponectinemia. Results show that CuE mediated these effects by attenuating Jenus kinase- Signal transducer and activator of transcription 5 (JAK- STAT5) signaling in visceral fat tissue. As a result, CuE treatment also reduced PPAR gamma expression. Glucose uptake enhanced in adipocytes after stimulation with CuE and insulin resistance diminished in mice treated with CuE, as reflected by reduced glucose intolerance and glucose stimulated insulin secretion. CuE restored insulin sensitivity indirectly by inhibiting JAK phosphorylation and improving AMPK activity. Consequently, insulin signaling was up-regulated in mice muscle. As CuE positively regulated adipose tissue function and suppressed visceral obesity, dyslipedemia, hyperglycemia and insulin resistance in mice model of MetS, CuE may be used as novel approach to treat metabolic diseases.
| ln Vitro |
Cucurbitacin E (CuE) was exposed to increasing concentrations of colorectal cancer (CRC) cell lines (0, 2.5, 5, and 7.5 μM) for a duration of 24 hours in an in vitro study to investigate the anticancer effect of CuE on CRC cells. We next used the MTT method to measure the proliferation of cancer cells treated with cucurbitacin E. For primary colon cancer cells, curcumin E promotes morphological alterations. Microscopically, cucurbitacin E (5 μM) treatment caused a considerable alteration in the morphology of primary colon cancer cells between 6 to 24 hours. By preventing the production of the GADD45γ gene and the cyclin B1/CDC2 complex in primary CRC cells, curcumin E inhibits the cell cycle in the G2/M phase of the cell cycle, which in turn stops its proliferation [1].
|
|---|---|
| ln Vivo |
The effects of cucurbitacin E (CuE) on body weight and adipose tissue biology were assessed using the high-fat diet mouse model of metabolic syndrome (HFD-MetS). When compared to HFD-MetS mice treated with vehicle alone, cucurbitacin E (0.5 mg/kg)-treated mice showed a significant reduction in body weight. In HFD-MetS mice, cucurbitacin E treatment decreased all fat pad weights. Following treatment with cucurbitacin E, mice's total fat decreased by 55% when compared to HFD-MetS mice. Metabolic syndrome is closely linked to abdominal obesity. Following cucurbitacin E treatment, central adiposity in HFD MetS mice was reduced to 50%, demonstrating the efficacy of cucurbitacin E in targeting MetS [2].
|
| References |
[1]. Hsu YC, et al. Therapeutic ROS targeting of GADD45γ in the induction of G2/M arrest in primary human colorectal cancer cell lines by cucurbitacin E. Cell Death Dis. 2014 Apr 24;5:e1198.
[2]. Murtaza M, et al. Cucurbitacin E reduces obesity and related metabolic dysfunction in mice by targeting JAK-STAT5 signaling pathway. PLoS One. 2017 Jun 9;12(6):e0178910 |
| Molecular Formula |
C32H44O8
|
|---|---|
| Molecular Weight |
556.6870
|
| CAS # |
18444-66-1
|
| Related CAS # |
Cucurbitacin B;6199-67-3;Cucurbitacin I;2222-07-3
|
| SMILES |
O[C@H](C1)[C@@]([C@@](C)(O)C(/C=C/C(OC(C)=O)(C)C)=O)([H])[C@](C2)(C)[C@]1(C)[C@]3([H])CC=C4C(C)(C)C(C(O)=C[C@@]4([H])[C@]3(C)C2=O)=O
|
| Synonyms |
Cucurbitacin E; α-Elaterin; α-Elaterine
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~89.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.49 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7963 mL | 8.9817 mL | 17.9633 mL | |
| 5 mM | 0.3593 mL | 1.7963 mL | 3.5927 mL | |
| 10 mM | 0.1796 mL | 0.8982 mL | 1.7963 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 Effect of cucurbitacins on adipogenesis.
CuE treatment improved insulin resistance in mice.PLoS One.2017 Jun 9;12(6):e0178910. |
|---|
 Effect of cucurbitacin E on body fat content.
Determination of the effect of CuE on insulin signaling.PLoS One.2017 Jun 9;12(6):e0178910. |
 Effect of CuE on adipose tissue morphology and function.
Determination of the effect of CuE on JAK-STAT signaling.PLoS One.2017 Jun 9;12(6):e0178910. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
